Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B brings in €14.1mm for ProtAffin

Executive Summary

ProtAffin AG (developing therapeutics for cancer and inflammatory conditions) has raised €14.1mm ($18.4mm) through its Series B venture round. New investors Atlas Venture and SR One Ltd. co-led and were joined by current backers Aescap Venture, Entrepreneurs Fund, and Z-Cube. Atlas and SR One will each gain representation on the board. The proceeds will be used to finish preclinical studies and Phase I trials of PA401, ProtAffin's lead drug candidate for chronic and acute inflammation.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies